Vertex Pharmaceuticals Incorporated (VRTX)
After hours:
| Previous Close | 401.08 |
| Open | 402.30 |
| Bid | 382.63 x 100 |
| Ask | 402.54 x 100 |
| Day's Range | 401.02 - 407.59 |
| 52 Week Range | 320.01 - 448.40 |
| Volume | |
| Avg. Volume | 1,045,123 |
| Market Cap | 104.03B |
| Beta (5Y Monthly) | 0.37 |
| PE Ratio (TTM) | 29.00 |
| EPS (TTM) | 13.88 |
| Earnings Date | May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 465.42 |
Investor's Business DailyVertex Beats Quarterly Forecasts, But Its Pipeline Remains Key
Vertex Pharmaceuticals beat first quarter sales and earnings forecasts, but investors are closely watching its pipeline updates.
ReutersVertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments
Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across 94 countries, according to data from U.S.-based CF Foundation. Sales from Vertex's top-selling CF drug Trikafta, also sold as Kaftrio in some markets, rose more than 18% from a year earlier to $2.48 billion in the quarter, beating analysts' expectations of $2.38 billion.
Business WireVertex Reports First Quarter 2024 Financial Results
BOSTON, May 06, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance.
